Related Experiment Video
Updated: Aug 8, 2025
07:11
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
Published on: May 25, 2020
6.4K
The Support, Educate, Empower personalized glaucoma coaching trial design.
Paula Anne Newman-Casey1,2, Ken Resnicow2,3, Suzanne Winter1
1Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA.
Clinical Trials (London, England)
|March 1, 2023
Summary
Personalized coaching significantly improved glaucoma medication adherence in a randomized trial. This intervention addresses adherence barriers, offering a scalable solution for better patient outcomes in glaucoma management.
Area of Science:
- Ophthalmology
- Public Health
- Behavioral Science
Background:
- Glaucoma affects 3 million Americans, often asymptomatic until advanced stages.
- Medication adherence is crucial but challenging, with over half of patients not taking prescribed drugs regularly.
- Late-stage diagnosis complicates treatment and increases the risk of irreversible peripheral vision loss.
Purpose of the Study:
- To enhance glaucoma medication adherence in patients with poor self-reported adherence.
- To evaluate the effectiveness of the Support, Educate, Empower personalized coaching program.
Main Methods:
- A two-site randomized controlled trial with 230 participants.
- Intervention group received personalized coaching and reminders; control group received usual care and general education.
- Primary outcome: proportion of prescribed doses taken on schedule over 6 months; secondary outcome: glaucoma-related distress.
Main Results:
- The study aims to determine if personalized coaching improves medication adherence compared to usual care.
- It will also assess the impact on glaucoma-related distress and intraocular pressure.
Conclusions:
- The personalized, motivational interviewing-based coaching program is designed to be comprehensive and address diverse adherence barriers.
- A web-based application ensures replicability and scalability for integration into clinical practice.
- This trial may inform future healthcare policy regarding reimbursement for such self-management support interventions.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
512
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
512
01:25Glaucoma: Overview
668
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
668
01:28Angle Closure Glaucoma: Treatment
602
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
602